IP Library › Granted Patent US 12,377,141
Granted Patent B2
US 12,377,141 · App. 17/417,596 · Granted Aug 5, 2025

Method for the expansion of HPV immunogen specific T-cells

Inventors: Hans Gronlund (Lidingö, SE); Ola Winqvist (Uppsala, SE)
Assignee: NEOGAP THERAPEUTICS AB
A61K39/12A61K40/11A61K40/428A61K40/46C12N5/0636A61K2039/5258A61K2039/55555A61K2039/892C12N2710/20011C12N2710/20023C12N2710/20034
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,377,141
App. No.
17/417,596
Granted
Aug 5, 2025
Kind
B2
Abstract

The present invention provides a method for the expansion of HPV immunogen specific T cells, comprising the steps of: i. providing a phagocytosable particle comprising a core and a human papillomavirus (HPV) immunogen tightly associated to the core; wherein the HPV immunogen has an amino acid sequence that corresponds to the amino acid sequence of a HPV protein, or has an amino acid sequence that corresponds to an amino acid sequence of a part of a HPV protein; ii. providing APCs; iii. contacting the phagocytosable particle comprising a core and a HPV immunogen with the APCs from step ii in vitro, and under conditions allowing phagocytosis of the HPV immunogen by the APCs; iv. providing T-cells that have been harvested from a subject; v. contacting the T-cells with the APCs from step iii) in vitro, and under conditions allowing specific activation of HPV immunogen specific T-cells. The invention further provides an expanded population of therapeutically useful T-cells and their use in the treatment or prevention of cancer, particularly HPV positive cancers.

Claims (21)

1. A method for the expansion of human papillomavirus (HPV) immunogen specific T-cells, comprising the steps of:

i. contacting a phagocytosable particle comprising a core and an HPV immunogen tightly associated to the core with antigen presenting cells (APCs) in vitro, and under conditions allowing phagocytosis of the HPV immunogen by the APCs, wherein:

(a) the core is paramagnetic or superparamagnetic and has a largest dimension of 0.5 μm to 2.5 μm; and

(b) the HPV immunogen has an amino acid sequence that corresponds to the amino acid sequence of an HPV protein, or has an amino acid sequence that corresponds to an amino acid sequence of a part of an HPV protein; and

contacting T-cells that have been harvested from a subject with the APCs from step i) in vitro, and under conditions allowing specific activation of HPV immunogen specific T-cells.

2. The method of claim 1 , n wherein the T-cells have been harvested from a subject having an HPV positive cancer.

3. The method of claim 1 , wherein the T-cells have been harvested from a tumour draining lymph node in the subject or from a PBMC sample derived from the subject.

4. The method of claim 1 , wherein the T-cells have been harvested from a PBMC sample derived from the subject, and wherein the subject is one that has previously received a dose of an HPV vaccine.

5. The method of claim 1 , wherein the HPV protein is one necessary for viral replication or an HPV coat protein.

6. The method of claim 1 , wherein the HPV protein is an HPV coat protein L1 selected from the group consisting of HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58.

7. The method of claim 1 , wherein the HPV immunogen is covalently attached to the core.

8. The method of claim 1 , wherein the core comprises polystyrene.

9. The method of claim 1 , wherein the phagocytosable particle comprises two or more HPV immunogens.

10. The method of claim 1 , wherein the phagocytosable particle comprises two or more different kinds of HPV immunogen.

11. The method of claim 4 , wherein the HPV vaccine comprises HPV coat protein L1 derived from HPV types 6, 11, 16 and 18.

12. The method of claim 4 , wherein the HPV vaccine comprises HPV coat protein L1 derived from HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58.

13. The method of claim 4 , wherein the HPV vaccine comprises HPV coat protein L1 derived from HPV types 6 and 11.

14. The method of claim 9 , wherein the HPV immunogens comprise HPV coat protein L1 derived from HPV types 6, 11, 16 and 18.

15. The method of claim 9 , wherein the HPV immunogens comprise HPV coat protein L1 derived from HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58.

16. The method of claim 9 , wherein the HPV immunogens comprise HPV coat protein L1 derived from HPV types 6 and 11.

17. The method of claim 1 , wherein the amino acid of the HPV immunogen comprises SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2023
From: GRÖNLUND, HANS; WINQVIST, OLA
To: NEOGAP THERAPEUTICS AB
Reel/Frame 065497/0232 →
Priority Claims (1)
GB 1821207 · Dec 24, 2018 · national
Continuity (1)
Related Publication 20220226457A1 · Jul 21, 2022
References Cited (117)
US 11360079B2 · Grönlund · 2022 [cited by applicant]
US 20040224402A1 · Bonyhadi et al. · 2004 [cited by applicant]
US 20080171059A1 · Howland et al. · 2008 [cited by applicant]
US 20160058853A1 · Sahin et al. · 2016 [cited by applicant]
US 20160101170A1 · Hacohen et al. · 2016 [cited by applicant]
US 20170072051A1 · Kaltenboeck et al. · 2017 [cited by applicant]
US 20170119668A1 · Keselowsky et al. · 2017 [cited by applicant]
US 20200140813A1 · Grönlund · 2020 [cited by applicant]
US 20220381771A1 · Grönlund · 2022 [cited by applicant]
US 20230310608A1 · Grönlund et al. · 2023 [cited by applicant]
CN 104338126A · 2015 [cited by examiner]
EP 2987494A1 · 2016 [cited by applicant]
EP 3182125A1 · 2017 [cited by applicant]
JP 2014523406A · 2014 [cited by applicant]
JP 2016501870A · 2016 [cited by applicant]
WO WO1992011030A1 · 1992 [cited by applicant]
WO WO2001017551A2 · 2001 [cited by applicant]
WO WO2003093511A1 · 2003 [cited by applicant]
WO WO2005013896A2 · 2005 [cited by applicant]
WO WO2008019366A2 · 2008 [cited by applicant]
WO WO2009076099A1 · 2009 [cited by applicant]
WO WO2011053331A1 · 2011 [cited by applicant]
WO WO2011085231A2 · 2011 [cited by applicant]
WO 2012159643A1 · 2012 [cited by applicant]
WO WO2014082729A1 · 2014 [cited by applicant]
WO WO2015009604A1 · 2015 [cited by applicant]
WO WO2016040900A1 · 2016 [cited by applicant]
WO WO2016053339A1 · 2016 [cited by applicant]
WO WO2016077215A2 · 2016 [cited by applicant]
WO WO2016154544A1 · 2016 [cited by applicant]
WO WO2016187508A2 · 2016 [cited by applicant]
WO WO2017087692A1 · 2017 [cited by applicant]
WO WO2017096304A1 · 2017 [cited by applicant]
WO WO2017102921A1 · 2017 [cited by applicant]
WO WO2018050818A1 · 2018 [cited by applicant]
WO WO2018182495A1 · 2018 [cited by applicant]
WO WO2018234516A2 · 2018 [cited by applicant]
Bellone, S., et al., 2009, Human papillomavirus type 16 (HPV-16) virus-like particle L1-specfic CD8+ cytotoxic T-lymphocytes (CTLs) are equally effective as E7-specific CD8+ Ctls in killing autologous HPV-16-positive tu… [cited by examiner]
Bellone, S., et al., Jul. 2009, Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-posit… [cited by examiner]
Unger, E., et al., Feb. 2017, Laboratory procedure manual: Human papillomavirus in serum-9-plex competitive luminex immunoassay (9-plex-cLIA,), retrieved from web.archive.org/web/w0q70225212457, 8 pages. [cited by examiner]
Luminex Corporation, May 2014, MAGPIX provides equivalent performance to the luminex 100/200 in an HPV vaccination trial, www.luminexcorp.com/download/magpix-provides-equivalent-performance-to-the-luminex-100200-in-an-h… [cited by examiner]
Perica, K., et al., 2015, Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy, ACSNANO, 9(7):6861-6871. [cited by examiner]
Bagarazzi et al., “Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses,” Science Translational Medicine, Oct. 10, 2012, vol. 4, Issue 155, p. 155ra138. [cited by applicant]
Bang Laboratories, Inc., “Ask the Particle Doctor,” 2011, pp. 1-69. [cited by applicant]
Bonaccorsi et al., “Acquisition and Presentation of Tumor Antigens by Dendritic Cells,” [cited by applicant]
Borst et al., “CD4+ T cell help in cancer immunology and immunotherapy,” [cited by applicant]
Borysiewicz et al., “A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer,” [cited by applicant]
Castle et al., “Exploiting the mutanome for tumor vaccination,” [cited by applicant]
Cho, N. et al., “A multifunctional core-shell nanoparticle for dendritic cell-based cancer immunotherapy,” [cited by applicant]
Chouhy et al., “Analysis of the genetic diversity and phylogenetic relationships of putative human papillomavirus types,” [cited by applicant]
Dianzani et al., “Association of Human Papillomavirus Type 11 with Carcinoma of the Penis,” [cited by applicant]
Forbes et al., “COSMIC: somatic cancer genetics at high-resolution,” [cited by applicant]
International Preliminary Report on Patentability, Chapter 1, Patent Cooperation Treaty Application No. PCT/EP2018/066690, Dec. 24, 2019, 13 pages. [cited by applicant]
International Preliminary Report on Patentability, Chapter 1, Patent Cooperation Treaty Application No. PCT/EP2019/087029, Jun. 16, 2021, 6 pages. [cited by applicant]
International Preliminary Report on Patentability, Chapter 1, Patent Cooperation Treaty Application No. PCT/EP2019/087030, Jun. 16, 2021, 7 pages. [cited by applicant]
International Search Report and Written Opinion, Patent Cooperation Treaty Application No. PCT/EP2018/066690, Jan. 15, 2019, 20 pages. [cited by applicant]
International Search Report and Written Opinion, Patent Cooperation Treaty Application No. PCT/EP2019/087029, Feb. 20, 2020, 12 pages. [cited by applicant]
Jiang et al., “Role of IL-2 in cancer immunotherapy,” [cited by applicant]
Karlsson et al., “Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancer,” [cited by applicant]
Kreiter et al., “Mutant MHC class Il epitopes drive therapeutic immune responses to cancer,” [cited by applicant]
Kuai, R., et al., “Designer vaccine nanodiscs for personalized cancer immunotherapy (includes Methods)” with supplementary information, [cited by applicant]
Kuai, R., et al., “Subcutaneous Nanodisc Vaccination with Neoantigens for Combination Cancer Immunotherapy” with supporting information, [cited by applicant]
Lee and Margolin, “Cytokines in cancer immunotherapy,” [cited by applicant]
Li, H. et al., “Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response,” [cited by applicant]
Marits et al., “Evaluation of T and B lymphocyte function in clinical practice using a flow cytometry based proliferation assay,” [cited by applicant]
Motoyama et al., “The role of human papilloma virus in the molecular biology of cervical carcinogenesis,” [cited by applicant]
Munoz et al., “Chapter 1: HPV in the etiology of human cancer,” [cited by applicant]
Pan et al., “Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: Implications for tumor suppressor gene function in development,” [cited by applicant]
Pittet et al., “Cutting Edge: Cytolytic Effector Function in Human Circulating CD8+ T Cells Closely Correlates with CD56 Surface Expression,” [cited by applicant]
Prickett, T.D. et al., “Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens,” [cited by applicant]
Qui, F., et al., “Poly(propylacrylic acid)-peptide nanoplexes as a platform for enhancing the immunogenicity of neoantigen cancer vaccines” with supporting information, [cited by applicant]
Rubin et al., “Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis,” [cited by applicant]
Shukla, G.S., et al.. , “Immunization with tumor neoantigens displayed on T7 phage nanoparticles elicits plasma antibody and vaccine-draining lymph node B cell responses,” [cited by applicant]
Stevanovic et al., “Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells,” [cited by applicant]
Svahn et al., “Development and evaluation of a flow-cytometric assay of specific cell-mediated immune response in activated whole blood for the detection of cell-mediated immunity against varicella-zoster virus,” Journa… [cited by applicant]
Thunberg et al., “Prolonged antigen-exposure with carbohydrate particle based vaccination prevents allergic immune responses in sensitized mice,” [cited by applicant]
Tornesello et al., “Human papillomavirus genotypes and HPV16 variants in penile carcinoma,”, International Journal of Cancer, Jan. 2008, vol. 122, Issue 1, pp. 132-137. [cited by applicant]
UK Search Report, Intellectual Property Office Patent Application No. GB 1821205.0, Sep. 11, 2019, 2 pages. [cited by applicant]
UK Search Report, Intellectual Property Office Patent Application No. GB 1821207.6, Sep. 3, 2019, 2 pages. [cited by applicant]
United States Office Action, U.S. Appl. No. 16/624,097, filed Apr. 18, 2022, 12 pages. [cited by applicant]
Yarchoan, M. et al., “Targeting neoantigens to augment antitumour immunity,” [cited by applicant]
Yoon et al., “Anti-tumor immunostimulatory effect of heat-killed tumor cells,” 2008, [cited by applicant]
Yuan, H. et al., “Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy,” [cited by applicant]
Bellone, S. et al., “Human Papillomavirus Type 16 (HPV-16) Virus-Like Particle L1-Specific CD8 [cited by applicant]
Herrin, D.M. et al., “Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus,” [cited by applicant]
International Search Report and Written Opinion, Patent Cooperation Treaty Application No. PCT/EP2019/087030, Mar. 9, 2020, 15 pages. [cited by applicant]
López-Toledo, G. et al., “Immunization with Human Papillomavirus 16 L1+E2 Chimeric Capsomers Elicits Cellular Immune Response and Antitumor Activity in a Mouse Model,” [cited by applicant]
Luminex Corporation, “MAGPIX Provides Equivalent Performance to the Luminex 100/200 in an HPV Vaccination Trial,” May 22, 2014 (May 22, 2014), [Online] [Retrieved Aug. 31, 2021], Retrieved from the Internet <URL:https:/… [cited by applicant]
Unger, E. et al., “Laboratory Procedure Manual: Human Papillomavirus in Serum—9-plex competitive Luminex Immuno Assay (9-plex cLIA),” Feb. 25, 2017 (Feb. 25, 2017), [Online][Retrieved Aug. 31, 2021], Retrieved from the … [cited by applicant]
Van Poelgeest, M. et al., “Potential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancer,” Cancer Immunology, Immunotherapy, Sep. 12, 2016 (Sep. 12, 2016), vol. 65, No. 12, p. 145… [cited by applicant]
Warrino, D. et al., “Human Papillomavirus L1L2-E7 Virus-Like Particles Partially Mature Human Dendritic Cells and Elicit E7-Specific T-Helper Responses from Patients with Cervical Intraepithelial Neoplasia or Cervical C… [cited by applicant]
Zhao, Q. et al., “Characterization of virus-like particles in GARDASIL® by cryo transmission electron microscopy,” [cited by applicant]
European Search Report issued Nov. 8, 2023 in connection with European patent application No. 23174945.8. [cited by applicant]
Berglund et al., 2023, “A first in human Phase I/lla trial of personalized Tumor-Trained Lymphocytes, pTTL, derived from regional lymph nodes for treatment of colorectal cancer”, poster presented at the Society for Immu… [cited by applicant]
Berglund et al., 2023, “A First in Human Phase I/IIA of Personalized Tumor-Trained Lymphocytes, PTTL, Derived From Regional Lymph Nodes for Treatment of Colorectal Cancer”, Journal for Immuno Therapy of Cancer, 11(Suppl… [cited by applicant]
Joly et al., 2022, “Personalized Tumour-Trained Lymphocytes Derived From Regional Lymph Nodes for Treatment of Colorectal Cancer”, Journal for ImmunoTherapy of Cancer, 10(Suppl 2):A1-A1603. [cited by applicant]
Joly et al., 2022, “Personalised tumour-trained lymphocytes derived from regional lymph nodes for treatment of colorectal cancer”, poster presented at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting. [cited by applicant]
Koppolu et al., 2013, “The effect of antigen encapsulation in chitosan particles on uptake, activation and presentation by antigen presenting cells”, Biomaterials, 34:2359-2369. [cited by applicant]
Tran et al., 2009, “The role of phagosomal pH on the size-dependent efficiency of cross-presentation by dendritic cells”, Biomaterials, 30:1356-1262. [cited by applicant]
Vidard et al., 1996, “Analysis of MHC class II presentation of particulate antigens of B lymphocytes”, 156(8):2809-2818. [cited by applicant]
Cameron, C.J., et al., “Artificial antigen presenting cells for use in adoptive immunotherapy,” [cited by applicant]
Mou et al., 2017, “The Effect of Superparamagnetic Iron Oxide Nanoparticle Surface Charge on Antigen Cross-Presentation”, Nanoscale Research Letters, 12(1):52. [cited by applicant]
Elamanchili et al., 2004, “Characterization of poly(D,L-lactic-co-glycolic acid) based on nanoparticulate system for enhanced delivery of antigens to dendritic cells,” Vaccine 22:2406-2412. [cited by applicant]
Elamanchili et al., 2007, “‘Pathogen-Mimicking’ Nanoparticles for Vaccine Delivery to Dendritic Cells,” J Immunother 30(4):378-395. [cited by applicant]
Fan et al., 2015, “Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy,” Vaccines 3:662-685. [cited by applicant]
Hobo et al., 2010, “siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells” Blood 116(22):4501-4511. [cited by applicant]
Joshi et al., 2012, “Targeting tumor antigens to dendritic cells using particulate carriers,” Journal of Controlled Release 161: 25-37. [cited by applicant]
Mayoux et al., 2020, “Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy,” Sci. Transl. Med. 12:1-11. [cited by applicant]
Rosenberg et al., 2015, “Adoptive cell transfer as personalized immunotherapy for human cancer,” Science 348(6230):62-68. [cited by applicant]
Yoshida et al., 2006, “Molecular aspects of microparticle phagocytosis by dendritic cells,” J Biomater: Sci. Polymer Edn 17(8):893-907. [cited by applicant]
Zhang et al., 2019, “Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade,” RSC Advances 9:33903-33911. [cited by applicant]
Zhao et al., 2019, “Amplified Cancer Immunotherapy of a Surface-Engineered Antigenic Microparticle Vaccine by Synergistically Modulating Tumor Microenvironment,” ACS NANO 13:12553-12566. [cited by applicant]
International Search Report mailed Oct. 15, 2021 in connection with PCT/EP2021/068267. [cited by applicant]
UK Search Report mailed Apr. 8, 2021 in connection with GB2010095.4. [cited by applicant]
Written Opinion mailed Oct. 15, 2021 in connection with PCT/EP2021/068267. [cited by applicant]
World Health Organization International Agency for Research on Cancer, 2007, “IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Human Papillomaviruses”, 90:1-689. [cited by applicant]
Pineo et al., 2013, “Immunogenic assessment of plant-produced human papillomavirus type 16 L1/L2 chimaeras”, Plant Biotechnology Journal, 11:964-975. [cited by applicant]